Log in

Relevant bibliographies by topics / Mood stabilizer drugs / Books

To see the other types of publications on this topic, follow the link: Mood stabilizer drugs.

Books on the topic 'Mood stabilizer drugs'

Author: Grafiati

Published: 24 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 17 books for your research on the topic 'Mood stabilizer drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Stahl, S. M. Mood stabilizers. Cambridge: Cambridge University Press, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

M, Stahl S., ed. Antipsychotics and mood stabilizers: Stahl's essential psychopharmacology, 3rd edition. Cambridge: Cambridge University Press, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Cavanna, Andrea E. Phenytoin. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198791577.003.0010.

Full text

Abstract:

Phenytoin is a first-generation antiepileptic drug characterized by a good range of antiepileptic indications, with an acceptable interaction profile in polytherapy. The reasons for the decreased use of phenytoin in patients with epilepsy include its narrow therapeutic index and potential for long-term toxicity, as well as the development of other antiepileptic drugs throughout the second half of the twentieth century. Phenytoin has a good behavioural tolerability profile and a restricted range of psychiatric uses. Despite occasional reports of adverse behavioural effects (especially at higher doses), there is some weak evidence for its potential usefulness as mood stabilizer and in the pharmacological management of impulsive aggression.

APA, Harvard, Vancouver, ISO, and other styles

4

Goldberg, Pablo H., Prerna Martin, Carolina Biernacki, and Moira A. Rynn. Treatments for Pediatric Bipolar Disorder. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0009.

Full text

Abstract:

The past two decades have seen significant advances in the development of evidence-based treatments for pediatric bipolar disorder. Practice guidelines recommend pharmacotherapy with mood stabilizers or second-generation antipsychotics (SGAs) as the first-line treatment. Lithium, risperidone, aripiprazole, quetiapine, and olanzapine are approved by the U.S. Food & Drug Administration for treating bipolar disorder in children and adolescents. The pharmacological literature suggests that SGAs are faster and more effective than mood stabilizers in treating acute manic or mixed episodes, but they have significant side effects and require careful monitoring. While mild to moderate bipolar disorder can be treated with monotherapy, combination pharmacotherapy with an SGA and a mood stabilizer is recommended for youth with severe bipolar disorder. A growing body of literature also suggests the efficacy of psychosocial interventions, with family psychoeducation and skills building as adjunct treatments to pharmacotherapy. More type 1 studies of pharmacotherapy and psychosocial treatments are needed.

APA, Harvard, Vancouver, ISO, and other styles

5

Stahl, Stephen M. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series). Cambridge University Press, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Barthel, Andreas, and Michael Bauer. Psychotropic drugs and metabolic risk. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198789284.003.0011.

Full text

Abstract:

Increased appetite and weight gain represent a significant problem related with particular antipsychotic drugs, antidepressants, mood stabilizers, and—to a lesser extent—anxiolytic drugs. Psychotropic drug-induced weight gain may contribute to obesity-related metabolic changes and pathological conditions such as dyslipidaemia, type-2-diabetes and hypertension—summarized as the metabolic syndrome—with an increased risk for cardiovascular morbidity and mortality. Interestingly, psychotropic drugs are also used for the treatment of diabetes-related complications. For example, antidepressants are effective for the treatment of neuropathic pain in patients with diabetic neuropathy. Therefore, it is essential to thoroughly balance potential benefits and risks in an individual patient to ensure drug safety and optimize the clinical outcome. In addition to diet and exercise, selection of psychotropic drugs and dose adjustment based on regular clinical follow-up visits is the key for the prevention and management of psychotropic drug induced weight gain in clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

7

Essential Psychopharmacology: the Prescriber's Guide: Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series). Cambridge University Press, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gupta, Neha. Treatment of Psychiatric Disorders. Edited by Isis Burgos-Chapman. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190265557.003.0006.

Full text

Abstract:

In this chapter, essential aspects of the treatment of psychiatric disorders are reviewed including pharmacokinetics, pharmacodynamics, drug interactions, psychogenomics and the use of antidepressants, mood stabilizers, antianxiety agents, antipsychotics, psychostimulants, hypnotics and sedatives, ECT and psychotherapy

APA, Harvard, Vancouver, ISO, and other styles

9

A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Perez-Rodriguez, M. Mercedes, and Larry J. Siever. Psychopharmacological Treatment of Personality Disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0028.

Full text

Abstract:

Despite the lack of approval by the U.S. Food & Drug Administration, drugs are used widely to treat personality disorders, particularly borderline personality disorder, based on their effects known from clinical trials in other psychiatric disorders (off-label use). The role of medications in personality disorders is limited to moderate effects on some but not all of the symptom domains. There are no medications available that improve the global severity of any personality disorder as a whole. In borderline personality disorder, evidence is strongest for second-generation antipsychotics and mood stabilizers, while dietary supplements like omega-3 fatty acids hold some promise. However, medications have limited effectiveness and are still viewed as adjunctive to other forms of treatment, particularly psychotherapy.

APA, Harvard, Vancouver, ISO, and other styles

11

Burns, Tom, and Mike Firn. The role of medication. Edited by Tom Burns and Mike Firn. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198754237.003.0007.

Full text

Abstract:

This chapter focuses mainly on the importance of maintenance antipsychotic medication and mood stabilizers. It examines procedures to support persistence with these drugs and maintain engagement. The techniques for initiating and monitoring clozapine therapy in the community for patients with resistant schizophrenia are outlined. The practical processes for ensuring and conducting regular structured reviews of long-term medication, both to assess progress and to identify side effects, are described in detail. In addition, the judicious use of antidepressants and benzodiazepines is outlined.

APA, Harvard, Vancouver, ISO, and other styles

12

Fabbri, Chiara, and Alessandro Serretti. The treatment of bipolar disorder in the era of personalized medicine: myth or promise? Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198748625.003.0031.

Full text

Abstract:

Bipolar disorder (BD) is a chronic disease associated with high personal and socio-economic burden. Genetics accounts for 20–95% of variability in central nervous system drug disposition and pharmacodynamics, thus genetic markers are considered a promising way to develop tailored treatments and improve the prognosis of the disease. Among mood stabilizers, lithium response was the most investigated phenotype and the most replicated genes are involved in synaptic plasticity (BDNF), serotonergic (SLC6A4) and dopaminergic (DRD1) neurotransmission, and second messenger cascades (GSK3B). Relevant pharmacogenetic findings regarding other mood stabilizers are hyperammonaemia (CPS1 gene) and hepatic dysfunction (POLG gene) induced by valproate and immune-mediated cutaneous hypersensitivity reactions (HLA-B*1502) induced by lamotrigine or carbamazepine. Polymorphisms in cytochrome (CYP) P450 genes are expected to provide useful information particularly in case of polypharmacy. Despite few pharmacogenetic tests are currently recommended, the development of pharmacogenetics in other fields of medicine provides an encouraging perspective.

APA, Harvard, Vancouver, ISO, and other styles

13

Series, Hugh. The Treatment of Depression. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780198801900.003.0010.

Full text

Abstract:

This chapter considers some of the physical options for the treatment of the affective disorders, depression, and mania. It first provides an historical overview of physical treatments for depression, including drugs such as opium, morphine, and diamorphine, chloral, and barbiturates, as well as electroconvulsive therapy (ECT). It then examines whether antidepressants work and how they are used before describing the biological basis of depression. It also looks at different classes of antidepressants, including monoamine oxidase inhibitors (MAOIs), reuptake inhibitors, and mood stabilizers. Finally, it evaluates non-pharmacological physical treatments ranging from ECT to transcranial magnetic stimulation (TMS), psychosurgery and deep brain stimulation, and novel therapies.

APA, Harvard, Vancouver, ISO, and other styles

14

Cavanna, Andrea E. Valproate. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198791577.003.0014.

Full text

Abstract:

Valproate is a first-generation antiepileptic drug characterized by a wide range of antiepileptic indications, with an acceptable interaction profile in polytherapy. Valproate has a good behavioural tolerability profile, despite the existence of occasional reports of depression, irritability, and other behavioural symptoms in patients with encephalopathy. Valproate is also characterized by a wide range of psychiatric uses. Most importantly, valproate is an effective mood stabilizser, with a licensed indication for the treatment of acute mania in patients with bipolar affective disorder. Although it has no formal indication, it is also considered as a first-line agent for maintenance treatment in bipolar affective disorder.

APA, Harvard, Vancouver, ISO, and other styles

15

Popovic, Dina, and Eduard Vieta. Evidence-based maintenance treatment of bipolar disorder. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198748625.003.0008.

Full text

Abstract:

Due to the episodic and chronic nature of bipolar disorder, maintenance therapy represents a critical part of treatment. However, there is a paucity of studies comparing effectiveness of available long-term treatments. In this chapter, the efficacy and safety of pharmacological treatments for maintenance treatment of bipolar disorder, as deriving from the results of randomized controlled trials, will be critically reviewed. These include second-generation antipsychotics aripiprazole, olanzapine, quetiapine, risperidone long-acting injection, ziprasidone, paliperidone, and mood stabilizers lamotrigine, lithium, valproate, carbamazepine, and oxcarbazepine. In general, if a patient has responded satisfactorily to a certain drug during the acute phase, the same treatment should be maintained during maintenance treatment. This was confirmed in two randomized controlled trials. This chapter summarizes the characteristics of the placebo-controlled randomized controlled trials for all the antipsychotics used for maintenance treatment of bipolar disorder.

APA, Harvard, Vancouver, ISO, and other styles

16

Kass, Erica, Jonathan E. Posner, and Laurence L. Greenhill. Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder and Disruptive Behavior Disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0004.

Full text

Abstract:

More than 225 placebo-controlled type 1 investigations demonstrate that psychostimulants are highly effective in reducing core symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adults. In contrast, there are limited type I studies demonstrating that psychopharmacological management with U.S. Food & Drug Administration-approved agents for ADHD (stimulants and nonstimulants), atypical antipsychotics, and mood stabilizers decrease the defiant and aggressive behavior characteristic of disruptive behavior disorders. Stimulant treatment evidence has been supplemented by two large multisite randomized controlled trials. Randomized controlled trials from the past 15 years continue to report several key adverse events associated with stimulants but have not supported rarer and more serious problems. Although psychostimulants have been shown to retain their efficacy for as long as 14 months, their long-term academic and social benefits are not as robust. Nonstimulant agents for which there is more limited evidence of efficacy include atomoxetine, alpha-agonists, modafinil, and bupropion.

APA, Harvard, Vancouver, ISO, and other styles

17

Ansari, Arash, and David Osser. Psychopharmacology. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780197537046.001.0001.

Full text

Abstract:

Psychopharmacology: A Concise Overview, 3rd Edition discusses and reviews currently available psychiatric medications and their evidence-supported use in current clinical practice. It discusses the therapeutic uses of antidepressants, anti-anxiety medications, antipsychotics, mood stabilizers, stimulants, and other medications for attention-deficit/hyperactivity disorder (ADHD), as well as medicines for substance use disorders. It reviews the medications’ mechanisms of action, therapeutic effects, potential drug–drug interactions and short- and long-term adverse effects and risks. It includes sections on complementary and alternative pharmacotherapies as well as on emerging therapies. Every chapter includes an in-depth discussion of the clinical use of the reviewed classes of medications as they are used for the alleviation of their target psychiatric disorders, such as depression, anxiety disorders, schizophrenia, bipolar disorder, ADHD, and opioid, alcohol, and tobacco use disorders. Treatment challenges and controversies are reviewed. In addition, each chapter discusses the use of these medications in other psychiatric and medical conditions as well. Each chapter also discusses the use of these medications in women of childbearing age, especially in light of pregnancy and breastfeeding considerations. Finally, each chapter includes a table that provides each reviewed medicine’s generic and brand names, usual adult doses, pertinent clinical comments, black box warnings, and Food and Drug Administration indications. This book provides a concise and accessible overview that would be helpful to medical students, psychiatric residents, psychiatrists, primary care physicians, clinical nurse specialists, and nonmedical mental health practitioners.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!